Arcadia Biosciences Responds to EU Court Ruling Regarding Regulation of Organisms Obtained by Mutagenesis
— Company’s health and nutrition ingredients, including GoodWheatTM platform of wheat innovations, are not affected by the ruling —
DAVIS, Calif. (August 7, 2018) – Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural food ingredient company, responded today to the recent ruling by the European Union (EU) Court of Justice regarding mutagenesis techniques and GMOs.
On July 25, 2018 the EU Court of Justice ruled that organisms resulting from modern mutagenesis techniques are subject to the same regulations as transgenic organisms containing genes from other species. As a result, the use of modern gene-editing technologies like CRISPR-Cas9 and others, may not be commercially viable for companies and academic researchers focused on improving plants to meet the challenges of a growing population in a time of climate uncertainty. The EU ruling also indicates that mutagenesis techniques currently regarded to be safe are exempt from the regulations.
“Arcadia is focused on commercializing traits developed using TILLING, a non-GM mutagenesis technique developed by Arcadia scientists and widely accepted as traditional plant breeding,” said Raj Ketkar, president and CEO of Arcadia. “Our proprietary TILLING libraries and pipeline of unique traits in soybeans, vegetables and wheat, including our GoodWheat ingredients, deliver innovative nutritional benefits for consumers and production benefits for growers, and are not subject to the EU ruling.
“However, Arcadia will continue to utilize innovations like CRISPR-Cas9 to accelerate commercialization of value-added plants in regions such as the U.S., where such modern gene-editing techniques are not regulated as GMOs,” Ketkar said. “We will leverage our unique TILLING capabilities along with other technologies to commercialize consumer food ingredients and crop enhancement traits, in line with the requirements of each geographical market.”
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ and affiliates’ ability to develop commercial products incorporating their traits, and complete the regulatory review process for such products; Arcadia’s compliance with laws and regulations that impact Arcadia’s business, and changes to such laws and regulations; Arcadia’s future capital requirements and ability to satisfy its capital needs; and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2017 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.